Physician profile
Arshad M Safi
NPI 1285635433
$1,267.67
in general payments reported to CMS, 2019-2025
18 companies · $264 in 2025
The $264 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $88.38 · 2020: $26.88 · 2021: $212 · 2022: $199 · 2023: $356 · 2024: $120 · 2025: $264.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $741.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $740.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $251.36 | 2019-2025 | Avvigo Guidance System, Watchman Access System |
| Abbott Laboratories | $209.91 | 2021-2023 | Mitraclip |
| Medtronic, INC. | $145.85 | 2022-2025 | Avalus, Ffrangio |
| E.R. Squibb & Sons, L.L.C. | $124.53 | 2020-2025 | Eliquis, Camzyos |
| Shockwave Medical, INC | $99.72 | 2021 | |
| Abiomed | $85.60 | 2024 | Impella |
| Philips North America LLC | $73.43 | 2023-2025 | Intrasight Integrated, Rotational |
| Sanofi-Aventis U.S. LLC | $50.62 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $46.39 | 2020-2022 | |
| Actelion Pharmaceuticals US, INC. | $28.49 | 2019 | |
| Novartis Pharmaceuticals Corporation | $25.02 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $24.02 | 2021 | |
| Medtronic Vascular, INC. | $21.11 | 2019 | |
| Chiesi USA, INC. | $17.74 | 2025 | Kengreal, Cleviprex |
| Bridgebio Pharma, INC. | $17.51 | 2025 | Attruby |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $15.65 | 2024 | |
| Getinge USA Sales, LLC | $15.56 | 2019 | |
| Amgen INC. | $15.16 | 2025 | Repatha |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arshad Safi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.